Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 27 May 2019, 13:37 HKT/SGT

Source: NEC Corporation
NEC Initiates AI-Driven Drug Discovery Business Targeting a Business Valuation of ¥300 Billion by 2025
- First Japan-based company to initiate clinical trials in development of individualized neoantigen vaccines -

TOKYO, May 27, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) will expand the application of its cutting-edge AI technologies, "NEC the WISE"(1), to cancer drug development that focuses on advanced immunotherapy as part of enhancing its healthcare business.

As a start, clinical trials for individualized neoantigen(2) vaccines will be initiated with Transgene SA (Transgene), making NEC the first company in Japan to initiate such trials.

The companies will target head and neck cancer and ovarian cancer with clinical trials that will be conducted in the United States and Europe. In April, an application to the United States Food and Drug Administration's (FDA) Investigational New Drug (IND) program received clearance to proceed with a Phase 1 clinical trial. Application submissions to the UK and France are currently under review. The investigational drug is being jointly developed by NEC and Transgene.

An estimated 18.1 million new cancer cases were diagnosed worldwide in 2018(3) and cancer is stated as the leading cause of death in Japan(4). There are great expectations in the development for better cancer treatments. This applies especially to cancer immunotherapy, which has been hailed as the next generation of cancer treatment, and utilizes a patient's own immune system to fight cancer.

NEC has an established history of working in close collaboration with academic institutions that include Kochi University and Yamaguchi University on research related to cancer drug discovery.

In recent years, the advent of genomic analysis has resulted in a massive growth in genome data, which has required artificial intelligence (AI) in order to be efficiently and accurately processed. NEC is aiming to see its AI-driven drug discovery business valued at ¥300 billion by 2025 through the development of more efficacious and safer immunotherapies.

In the development of individualized neoantigen vaccines, the selection of target neoantigens is crucial. NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. As such, NEC is able to effectively prioritize the numerous candidate neoantigens identified in a single patient. This unique approach has resulted in NEC's acceptance into the Tumor neoantigEn SeLection Alliance (TESLA) consortium, thereby allowing NEC to actively contribute to this global research initiative which seeks to improve cancer treatment.

NEC is committed to the provision of social solutions that promote an equal and prosperous society that embraces diversity and allows all individuals to play an active role.

Development of individualized immunotherapy with cutting-edge AI technology

"The advent of individualized immunotherapies calls for new business paradigms and thus new types of alliances. We are confident that Transgene and NEC have established a strong technological foundation with great synergies for the co-development of our individualised neoantigen vaccine, TG4050," said Eric Quemeneur, Pharm.D., Ph.D., Executive Vice President and Chief Scientific Officer of Transgene. "We look forward to capitalizing on our synergistic expertise and complementary business development efforts."

(1) NEC the WISE
NEC's cutting-edge portfolio of AI technologies
(2) Neoantigen:
Newly generated cancer antigens associated with genetic mutations in cancer cells. Neoantigens are not expressed in normal cells, but are found only in cancer cells, many of which vary from patient to patient.
(3) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
(4) 2017 demographic statistics from Japan's Ministry of Health, Labour and Welfare

About NEC Corporation

NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at

Seiichiro Toda

May 27, 2019 13:37 HKT/SGT
Topic: Press release summary
Sectors: Enterprise IT
From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

NEC Corporation Links

NEC Corporation
June 26, 2019 17:04 HKT/SGT
NEC Participates in INTERPOL World 2019
June 25, 2019 16:08 HKT/SGT
NEC and Samsung Enhance Global Sales Structure for 5G Solutions
June 20, 2019 14:09 HKT/SGT
NEC Fingerprint Identification Contributes to the Provision of Legal Identity for Newborn Children in Developing Countries
June 18, 2019 14:26 HKT/SGT
NEC to Deploy Direct-Liquid Cooled, AMD EPYC Processor Powered Supercomputer for the German Aerospace Center (DLR)
June 18, 2019 10:10 HKT/SGT
NEC Partners with C-DAC to Deploy Automated Fingerprint Identification System for Kerala State Police in India
June 17, 2019 17:07 HKT/SGT
NEC Receives EUR50 Million Order from Deutscher Wetterdienst (DWD)
June 13, 2019 10:21 HKT/SGT
NEC Introduces Unique, Adaptive Energy Warranty to Optimize Value for Energy Storage Customers
June 11, 2019 10:00 HKT/SGT
NEC and Aviat Sign Channel Partner Agreement for North America Microwave Business
June 10, 2019 16:05 HKT/SGT
NEC Provides TOP500 Supercomputer to RWTH Aachen University in Germany
June 6, 2019 10:00 HKT/SGT
Gavi, NEC, and Simprints to Deploy World's First Scalable Child Fingerprint Identification Solution to Boost Immunization in Developing Countries
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: